Shi Yan, Liu William, Hu Junming, Qiu Wei Qiao, He Xinyue, Gao Yan, Zhang Xiaoling, Fan Zhigang
Beijing Tongren Eye Center Research Ward, Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing Tongren Hospital, Beijing Institute of Ophthalmology, Capital Medical University, Beijing, China.
Yale University, New Haven, Connecticut.
Ophthalmol Sci. 2025 Jan 31;5(4):100726. doi: 10.1016/j.xops.2025.100726. eCollection 2025 Jul-Aug.
To explore the impact of menopause for age at diagnosis (AAD) of glaucoma in women and illustrate its interaction with the apolipoprotein E () E4 allele.
A retrospective, case-only analysis using the UK Biobank participants with complete data (2006-2010) for analysis.
One thousand three hundred fifty-eight female glaucoma patients.
Multivariable-adjusted associations of AAD of glaucoma, E4 allele, age of menopause, and hormone replacement therapy (HRT) were analyzed by linear mixed model (LMM) analyses across groups stratified by whether glaucoma developed before or after menopause and whether or not HRT was used.
Age at diagnosis of glaucoma, age of menopause, E4 allele, and HRT information.
The age-adjusted univariate LMM showed that later menopause was significantly associated with an older AAD of glaucoma in both the overall cohort and subgroups where glaucoma developed before or after menopause (model 1, all < 0.05). The age-adjusted multivariate LMM found that carrying the E4 allele combined with later menopause significantly increased the AAD of glaucoma in patients diagnosed before menopause (model 3: β = 0.711 ± 0.074, < 0.001; β = 1.406 ± 0.596, = 0.019; model 1 vs. model 3: = 0.018). No similar association was observed in patients diagnosed after menopause ( > 0.05). Additionally, the age-adjusted univariate LMM showed that HRT was associated with an older AAD of glaucoma (model 4: β = 1.239 ± 0.368, = 0.001), with this effect being more pronounced in patients with later menopause (model 5: β = 1.625 ± 0.356, < 0.001; β = 0.301 ± 0.033, < 0.001; model 4 vs. model 5: < 0.001).
Later menopause was associated with an older AAD of glaucoma, with the E4 allele providing increased protection against glaucoma in those diagnosed before, but not after, menopause. The protective effect of later menopause was also enhanced by HRT use after menopause. These findings underscore the interaction of hormonal status and genotype in glaucoma onset, potentially guiding the prevention or management of glaucoma and other age-related health conditions in women.
The author(s) have no proprietary or commercial interest in any materials discussed in this article.
探讨绝经对女性青光眼诊断年龄(AAD)的影响,并阐明其与载脂蛋白E()E4等位基因的相互作用。
一项回顾性、仅病例分析,使用英国生物银行中具有完整数据(2006 - 2010年)的参与者进行分析。
1358名女性青光眼患者。
通过线性混合模型(LMM)分析,对青光眼诊断年龄、E4等位基因、绝经年龄和激素替代疗法(HRT)进行多变量调整后的关联分析,分析对象按青光眼在绝经前或绝经后发病以及是否使用HRT进行分组。
青光眼诊断年龄、绝经年龄、E4等位基因和HRT信息。
年龄调整后的单变量LMM显示,在整个队列以及青光眼在绝经前或绝经后发病的亚组中,绝经较晚均与青光眼的诊断年龄较大显著相关(模型1,所有<0.05)。年龄调整后的多变量LMM发现,携带E4等位基因且绝经较晚显著增加了绝经前诊断的患者的青光眼诊断年龄(模型3:β = 0.711 ± 0.074,<0.001;β = 1.406 ± 0.596,= 0.019;模型1与模型3比较:= 0.018)。在绝经后诊断的患者中未观察到类似关联(>0.05)。此外,年龄调整后的单变量LMM显示,HRT与青光眼的诊断年龄较大相关(模型4:β = 1.239 ± 0.368,= 0.001),这种效应在绝经较晚的患者中更为明显(模型5:β = 1.625 ± 0.356,<0.001;β = 0.301 ± 0.033,<0.001;模型4与模型5比较:<0.001)。
绝经较晚与青光眼的诊断年龄较大相关,E4等位基因在绝经前诊断的患者中对青光眼提供了更强的保护,但在绝经后则不然。绝经后使用HRT也增强了绝经较晚的保护作用。这些发现强调了激素状态和基因型在青光眼发病中的相互作用,可能为女性青光眼及其他与年龄相关的健康状况的预防或管理提供指导。
作者对本文讨论的任何材料均无所有权或商业利益。